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Synergistic regulation of serotonin- and opioid 1 
signaling contribute to pain-insensitivity in 2 
Nav1.7-/- mice 3 
We show for the first time that a voltage gated sodium channel such as Nav1.7 4 
controls intracellular pain signaling pathways and that loss of Nav1.7 shifts the 5 
homeostatic balance from pro- to anti-nociceptive signaling. 6 
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Abstract 18 
Loss of the voltage-gated sodium channel Nav1.7 results in lifelong insensitivity to 19 
pain in humans and mice. This seems to involve the upregulation of endogenous 20 
opioid precursors. If there are changes of intracellular pain signaling and if the 21 
opioid signaling can escape changes compensating the increased extracellular 22 
opioids in Nav1.7-/- is unknown. We now analyzed the balance of pro- and anti-23 
nociceptive GPCR signaling using a novel cell-based assay for the activity of 24 
endogenous type II protein kinase A (PKA-II) in sensory neurons. Contrary to 25 
expected upregulation of counterbalancing pro-nociceptive signaling, we show that 26 
loss of Nav1.7 decreases the pro-nociceptive serotonergic 5-HT4 receptor and its 27 
intracellular mediator, PKA-RIIβ. Simultaneously, the efficacy of anti-nociceptive 28 
opioid signaling is not reduced but strongly increased lowering efficiently TTX-r 29 
currents in nociceptive neurons. Thus Nav1.7 controls the intracellular homeostatic 30 
interplay of pro- and anti-nociceptive signaling in a synergistic and long-lasting 31 
manner contributing to lifelong endogenous analgesia. 32 
Introduction 33 
Novel strategies to treat pain are urgently required as over 20% of patients do not 34 
respond to current analgesics (1, 2). In addition, therapy with existing analgesics 35 
requires urgent improvement. Opioids, which are considered benchmark 36 
analgesics, achieve only 10-15% pain relief on average (3-5). Beyond the problem 37 
of in part severe side-effects (6, 7), one aspect further compounding the use of 38 
opioids is that patients quickly desensitize and thereby require ever increasing 39 
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doses. Despite extensive research, at present desensitization due to the prolonged 40 
presence of opioids can only be reduced but not abolished (8).  41 
Voltage-gated sodium channels such as Nav1.7 are central for the sensitivity and 42 
activation of nociceptive neurons in response to pain-initiating stimuli. Loss of 43 
function of Nav1.7 results in lifelong absence of pain in mice and humans which, 44 
apart from anosmia, are otherwise seemingly normal (9-11). The central role of 45 
Nav1.7 in pain and its predominant expression in nociceptive neurons makes it an 46 
excellent potential target for novel drugs. This topic is currently under intense 47 
academic and commercial investigation (12, 13). Nevertheless, potent Nav1.7 48 
blockers fail to alleviate pain (14).  49 
The exact mechanisms responsible for pain insensitivity due to loss of Nav1.7 are 50 
incompletely understood (12). Surprisingly, it was recently reported that Nav1.7-51 
deficiency upregulates the expression of met-enkephalin in sensory neurons and 52 
that blocking opioid receptors with naloxone recovers the ability to perceive pain in 53 
Nav1.7 null mice and humans (15). These data indicate that, in addition to its role in 54 
electrical signaling, Nav1.7 is likely to have other functions which contribute to pain 55 
sensitivity substantiating its potential as an exciting analgesic drug target. If Nav1.7 56 
controls only the expression of the extracellular opioid, if an increase in 57 
extracellular opioids is necessary for a reduced nociceptor activity, or if NaV1.7 also 58 
changes long-term intracellular analgesic signaling is currently unknown. 59 
Pain sensitivity is strongly regulated by balancing the interplay of pro- and anti-60 
nociceptive signaling (16, 17). Gene expression profiling in dorsal root ganglia of 61 
Nav1.7-deficient mice indicated the downregulation of the metabotropic serotonin 62 
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receptor 5-HT4 (15). This suggests that Nav1.7 may control an even more profound 63 
change than merely increased opioid ligand expression by changing both, the pro- 64 
and anti-nociceptive intracellular signaling. Whether Nav1.7 thereby controls 5-HT4 65 
receptor-mediated intracellular pro-nociceptive signaling, and whether this acts 66 
synergistically with the increased opioid expression in the very same cell remains 67 
to be investigated with single cell resolution.  68 
Using a novel assay for the activation of type II protein kinase A (PKA-II) and 69 
quantifying more than one million single primary neurons demonstrates that Nav1.7 70 
controls both pro- and anti-nociceptive cellular inputs resulting in increased opioid-71 
receptor signaling and, in the same neurons, in a synergistic and sustained 72 
decrease in 5-HT activity resulting in strongly increased opioid efficacy on TTXr 73 
currents. Thus, Nav1.7 appears to control the homeostatic set point of the 74 
counterbalancing pro- and anti-nociceptive intracellular signaling cascades. 75 
Results 76 
We set out to characterize if loss of NaV1.7 and the concomitant long-term 77 
upregulation of opioid-precursors (15) alters intracellular signaling. Specifically, we 78 
tested for changes in the pro-nociceptive and PKA-activating serotonin signaling as 79 
well as its counterbalancing PKA-inhibiting antagonistic opioid signaling. To do so, 80 
first, it needed to be identified, which 5HT receptor has the strongest influence on 81 
pro-nociceptive PKA signaling as well as to develop a system to monitor the 82 
interplay of 5HT-signaling and opioid signaling in adult primary neurons on a single 83 
cell level. 84 
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5-HT4 receptor is critical for the activation of PKA-II 85 
Which of the Gαs coupled metabotropic serotonin receptors (5-HT4, 5-HT6, 5-HT7) 86 
drive PKA activation in nociceptive neurons thus far remained controversial (18-87 
20). Recently, we introduced a “High Content Screening (HCS)” microscopy 88 
approach to detect the phosphorylated form of PKA-II regulatory subunits RIIα and 89 
RIIβ (pRII) for the analysis of endogenous cAMP/PKA dynamics in sensory 90 
neurons (21, 22) (Fig. 1A, B). Using this assay we now observed that 5-HT as well 91 
as the 5-HT4-specific agonist SC-53116 (23) increased phospho-RII (pRII) intensity 92 
with similar potency in rat sensory neurons after 3 min stimulation (Fig. 1C, 93 
EC50 = 30 nM and 89 nM, respectively). The 5-HT response was fully blocked by 94 
the 5-HT4-specific antagonist GR113808 (24) indicating that the 5-HT4 receptor is 95 
both sufficient and necessary for 5-HT-induced pRII sensitization-signaling in 96 
sensory neurons (Fig. 1D, IC50 = 8.6 nM). Thus, the downregulation of 5-HT4 97 
mRNA in Nav1.7-/-, as identified in Minett’s et al. transcriptome data (15), indicate 98 
the potential reduction of an important pro-nociceptive signaling pathway.  99 
Opioids inhibit 5-HT-induced PKA-II activation 100 
To examine if the upregulation of opioids could attenuate 5-HT signaling on a 101 
single cell basis, we extended our recent pRII HCS microscopy approach to 102 
monitor not only pro- but also anti-nociceptive GPCR signaling. We increased 103 
endogenous pRII signals with a 5-HT test stimulus and observed opioid activity as 104 
a reduction in the 5-HT-induced pRII signal. Indeed, the clinically relevant opioid 105 
analgesic fentanyl and also the µ-opioid-receptor (MOR)-specific agonist DAMGO 106 
dose-dependently inhibited the 5-HT (200 nM)-induced pRII signal (Fig. 1E) in rat 107 
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sensory neurons. As expected, fentanyl was more potent than DAMGO (IC50 = 108 
97 nM vs. 321 nM, F1,47 = 4.2, n = 4, P < 0.05 for pIC50, extra-sum-of-squares F 109 
test). Co-application of fentanyl with 5-HT produced long-lasting inhibition of 5-HT-110 
responses at all tested doses (F3,84 = 77.2, n = 4, P < 2e-16, two-way ANOVA), 111 
while basal pRII intensity was not affected (Fig. 1F). The competitive opioid 112 
receptor antagonist naltrexone (NTX, 10 µM) completely reversed the fentanyl-113 
induced inhibition of pRII intensity (F1,42 = 136, n = 4, P < 9.5e-15, two-way 114 
ANOVA, Fig. 1G). NTX had no effect on basal or 5-HT-induced pRII intensity, 115 
which demonstrates the absence of constitutive opioid receptor activity in cultured 116 
rat sensory neurons (Fig. 1H). Also the MOR-specific antagonist CTOP (10 µM) did 117 
not affect baseline or 5-HT induced pRII intensity, but only partially reverted the 118 
fentanyl-induced inhibition of pRII (F1,42 = 12, n = 4, P < 0.01, two-way ANOVA, 119 
Fig. 1I-J). Applying the MOR-specific agonist DAMGO resulted in a similar dose-120 
dependent inhibition of 5-HT-induced pRII immunoreactivity (F3,56 = 51, n = 3, 121 
P < 5e-16, two-way ANOVA, Fig. 1K), which was fully reversed by NTX (Fig. 1L) 122 
and partially by CTOP (Fig. 1M). Further experiments demonstrated that opioids 123 
also inhibit PKA-II activity induced by the IP1 receptor agonist prostacyclin (PGI2) or 124 
the adenylyl cyclase activator forskolin (Fsk) (Supplementary Fig. S1).  125 
To investigate if opioids and 5-HT act on the same subgroup of nociceptive 126 
neurons, we performed co-stainings of pRII with RIIβ after stimulation with Fsk 127 
(2 µM), 5-HT (0.2 µM) or PGI2 (1 µM) while activating opioid receptors with fentanyl 128 
(2 µM) (Fig. 2A). We recently identified RIIβ as a novel integrative marker of 129 
nociceptors that is coexpressed with opioid receptors (21, 25). After compensating 130 
for potential spill-over between fluorescence channels (Fig. 2B), we found that Fsk 131 
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increased the pRII intensity levels in all rat sensory neurons, including RIIβ(-) 132 
neurons, whereas 5-HT and PGI2 were predominately activating RIIβ(+) neurons 133 
(Fig. 2A, C, D). Confirming that RIIβ predicts sensitivity to opioids, we found 134 
inhibitory effects of fentanyl on Fsk-induced pRII to be restricted to the RIIβ(+) 135 
subgroup (Fig. 2A, C, D).  136 
5-HT signaling is reduced in Nav1.7-/- mice 137 
Next, we tested if loss of Nav1.7 results in long-lasting changes in nociceptors in 138 
addition to the reported upregulation of the opioid ligand, pre-proenkephalin (15). 139 
More specifically, we analyzed the counterbalancing between the pro-nociceptive 140 
serotonergic signaling by 5-HT4 receptors and the anti-nociceptive opioid system at 141 
the level of their intracellular mediator cAMP/PKA-II in pain-insensitive Nav1.7-/- 142 
mice and Nav1.8-/- mice (10, 26). General features such as the pRII increase after 143 
Fsk treatment (10 µM), cell numbers, cell size and neuronal marker (UCHL1) 144 
distribution were highly similar indicating comparability among the genotypes 145 
(Fig. 3A-D).  146 
Using qPCR, we corroborated the downregulation of 5-HT4 receptors in sensory 147 
ganglia of Nav1.7-/- mice identified in a microarray by Minett et al. (15) (Fig. 3E). In 148 
contrast, 5-HT4 receptor mRNA levels remained unchanged in Nav1.8-/- mice 149 
(Fig. 3F). To test for accompanying functional cellular changes at the level of 150 
GPCRs, adenylyl cyclase, and PKA-II, we performed dose response experiments 151 
with 5-HT, PGI2, Fsk, and the cell-permeable cAMP analog Sp-8-Br-cAMPS-AM 152 
(Fig. 3G-K). Corroborating our finding of reduced expression of 5-HT4 receptor 153 
mRNA, specifically pRII responses to 5-HT but not PGI2, Fsk, or Sp-8-Br-cAMPS-154 
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AM were reduced in sensory neurons of Nav1.7-/- mice (Fig. 3G, H). Confirming 155 
decreased receptor abundance, only the maximum amplitude of the response was 156 
significantly reduced by 37% (F1,64 = 53.6, n = 5, P < 0.0001, extra-sum-of-squares 157 
F test), while the EC50 values remained unchanged (Fig. 3H). In addition to the 158 
reduced average signal amplitude, also the number of responding cells was 159 
reduced in Nav1.7-/- mice as evaluated by thresholding the single cell data (see 160 
Fig. 3G at 1 µM 5-HT: 19.1 ± 1.2% in Nav1.7-/- vs. 27.8 ± 1.3% in Nav1.7+/+, n = 5, 161 
P < 0.001, Student’s t-test). In contrast, responses to PGI2 were not altered, 162 
indicating specificity for 5-HT/5-HT4 receptors (Fig. 3I). In addition, dose-responses 163 
of the downstream activators Fsk and Sp-8-Br-cAMPS-AM were similar in both 164 
genotypes (Fig. 3J, K) corroborating a primary change at the receptor level.  165 
RIIβ is downregulated in Nav1.7-/- mice 166 
The pRII dose response data in Fig. 3H-K were normalized. But not-normalized 167 
data as presented in the kinetic experiments of Fig. 4D revealed an additional 168 
reduction of pRII baseline intensity values by 8% in Nav1.7-/- mice compared to 169 
wildtype litters (F1,36 = 22.9, n = 4, P < 3e-05, two-way ANOVA). This was highly 170 
unexpected, since the baseline activity of PKA-II is commonly tightly controlled and 171 
maintained at a constant level. Thus, the newly observed reduction in baseline 172 
activity indicates a further intracellular alteration induced by the loss of Nav1.7. 173 
Thereby, the reduced pro-nociceptive 5-HT4 receptor input is further reduced on 174 
the level of intracellular signaling. As for 5-HT4 receptors, this effect was specific 175 
for Nav1.7-/- mice and absent in Nav1.8-/- mice (Fig. 4K-Q).  176 
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A reduction of the pRII levels could be the result of reduced expression or reduced 177 
phosphorylation of the respective regulatory subunits. We therefore analyzed the 178 
abundance of RIIβ, the major PKA-RII regulatory subunit in rat nociceptive neurons 179 
(21). In mice we also found RIIβ to be enriched especially in small-to-medium sized 180 
sensory neurons (Fig. 4A, B). Nav1.7-deficiency did not affect the number of 181 
RIIβ(+) neurons (47.1 ± 1.2% vs. 48.7 ± 0.3%), but resulted in a general shift 182 
towards lower RIIβ intensities. Indeed, mean RIIβ intensities were 11% lower in 183 
RIIβ(+) neurons of Nav1.7-/- mice compared to wildtype litters (1589 ± 19 vs. 184 
1779 ± 34, n = 5, P < 0.0001, two-way ANOVA with Bonferroni’s test) (Fig. 4C). 185 
Downregulation of 5-HT4-mediated input and of the RIIβ-mediator could be 186 
compensated by e.g. an increased homeostatic PKA-activity. But, not only the RIIβ 187 
intensities but also the phosphorylation signals of pRII were lower in Nav1.7-/- mice 188 
(Fig. 4D-J). The phosphorylation signals remained lower than in wildtype also in 189 
response to Fsk stimulation (Fig. 4J). This effect was again specific to Nav1.7-/- 190 
mice as it was absent in Nav1.8-/- mice. 191 
Opioid signaling is amplified in Nav1.7-/- mice 192 
Having established a synergistic downregulation of the 5-HT4 receptor input as well 193 
as of the intracellular mediator RIIβ, we next investigated the effect of Nav1.7 and 194 
Nav1.8 on the cellular activity of the common antipode of sensitization, the anti-195 
nociceptive opioid receptor system.  196 
We tested the effect of fentanyl (2 µM) and NTX (10 µM) on changes of pRII 197 
intensity. Treatment with neither fentanyl nor NTX altered the baseline pRII levels 198 
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in neurons from Nav1.7-/- or Nav1.8-/- mice (Fig. 4E, F, L, M). Thus, not only 199 
wildtype rat nociceptors (Fig. 1G, H), but also murine cells from Nav1.7-/- mice did 200 
not show any constitutive opioid receptor activity in culture.  201 
Next we tested the effect of fentanyl and NTX on changes of pRII intensity induced 202 
by 5-HT. Commonly, prolonged opioid exposure as suspected to be the case in 203 
Nav1.7-/- mice induces desensitization. In contrast, we now found the inhibition of 204 
the 5-HT-signaling by fentanyl to be substantially amplified in sensory neurons of 205 
Nav1.7-/- mice (F1,35 = 37, n = 4, P < 6e-07, two-way ANOVA, Fig. 4H). While 206 
there was few reduction of 5-HT-induced pRII signals in wildtype animals (Fig. 4G 207 
vs. 4H, black line), fentanyl completely abolished the 5-HT response in Nav1.7-/- 208 
mice (Fig. 4G vs. 4H, red line). This fentanyl effect was indeed opioid receptor 209 
mediated as NTX effectively antagonized the fentanyl effect (Fig. 4I). Again, this 210 
phenotype was absent in Nav1.8-/- mice suggesting a specific role of Nav1.7 in 211 
regulating intracellular opioid-receptor signaling (Fig. 4K-Q). 212 
To analyze how these differences of averaged response signals distribute over 213 
subgroups of sensory neurons, we plotted the pRII intensities of all analyzed 214 
neurons versus their size and applied a fixed threshold to evaluate the number of 215 
responding neurons (Fig. 4R). Stimulation with 5-HT for 1 min increased pRII 216 
signals in 17% of smaller sized sensory neurons from Nav1.7-/- mice and in 21% 217 
from wildtype litters, respectively. Simultaneous application of fentanyl reduced the 218 
number of 5-HT responsive neurons from 17% to 6% in Nav1.7-/- and from 21% to 219 
17% in wildtypes (Fig. 4R, red arrow). Thus, not only the signaling amplitude but 220 
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also the number of cells responding to 5-HT in the presence of fentanyl was much 221 
reduced in Nav1.7-/- animals. 222 
The pro- and anti-nociceptive input is considered to be balanced at a single cell 223 
level in a stimulus-response relationship (27). Thus, a reduced 5-HT pro-224 
nociceptive input should result in a less effective anti-nociceptive dose-response 225 
relationship, i.e. an increased IC50. We tested for the dose-response relationship of 226 
fentanyl onto one constant 5-HT (0.2 µM) response (Fig. 5A, B). Interestingly, the 227 
IC50 values were not significantly different between the two genotypes suggesting a 228 
similar receptor-ligand affinity (IC50 = 16 vs. 36 nM in Nav1.7-/- mice and wildtype 229 
litters). Nevertheless, we observed a substantial reduction in the response 230 
amplitude of fentanyl over the full dose-response-curve in Nav1.7-/--deficient 231 
neurons (Fig. 5A, F2,56 = 13.6, n = 4, P < 0.0001, extra-sum-of-squares F test). This 232 
was similarly reflected in the subpopulation data (Fig. 5B). While even high doses 233 
of opioids left a substantial proportion of wildtype RIIβ(+) neurons responding to 5-234 
HT (Fig. 5B, upper panel), fentanyl reduced pRII levels to almost baseline in 235 
Nav1.7-deficient neurons indicating strongly increased effectiveness of the opioid 236 
system (Fig. 5B, lower panel). Very similar results were obtained for DAMGO 237 
(F2,36 = 7.7, n = 3, P < 0.01, extra-sum-of-squares F test, IC50 = 155 vs. 250 nM in 238 
Nav1.7-/- mice and wildtype litters, Supplemental Fig. S2).  239 
Next we tested if the enhanced effectiveness of the opioid system is restricted to 5-240 
HT or if this is a general phenomenon. To analyze this independent of the 241 
stimulatory GPCR input, we stimulated sensory neurons for 3 min with increasing 242 
doses of fentanyl in the presence of Fsk (2 µM). The effectiveness of fentanyl was 243 
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again strongly enhanced in Nav1.7-deficient neurons (Fig. 5C, F1,50 = 32, n = 4, 244 
P < 0.0001 for bottom values; extra-sum-of-squares F test). Analyzing the single 245 
cell data showed that the number of Fsk-stimulated neurons were 23.1 ± 0.4% 246 
(Nav1.7-/-) vs. 28.4 ± 2.6% (Nav1.7+/+) in the absence of fentanyl (n = 4, P < 0.01, 247 
Student’s t-test). Application of fentanyl (2 µM) reduced the number of Fsk-248 
responsive neurons to 9.0 ± 0.6% in Nav1.7-/- vs. 17.0 ± 0.7% in wildtype litters 249 
(n = 4, P < 0.0001, Student’s t-test). Thus, the relative as well as the absolute 250 
reduction of the responding cell number was substantially increased in Nav1.7-/- 251 
(Fig. 5D). 252 
Synergistic dampening of pain signaling renders opioids more 253 
effective on sodium current reduction 254 
Finally we tested if the general and long-lasting increased effectiveness of the 255 
opioid system can also be measured on functional downstream effectors of the 256 
PKA system. PKA shows a strong sensitization of the Nav1.8 encoded TTX-r 257 
current in nociceptive neurons, which contributes to nociceptive drive. We used in 258 
vitro cultures of sensory neurons from wild type and Nav1.7-/- mice to examine the 259 
level of expression of TTXr sodium currents and the effect of fentanyl. Consistent 260 
with the cellular studies of PKA activity, we found that fentanyl lowered the 261 
expression of Nav1.8 TTXr currents twice as effectively in Nav1.7-/- mice than in 262 
their wild type littermates. This demonstrates that the mechanistic studies carried 263 
out in cell-based assays are relevant to the control of nociceptive drive by opioids 264 
in sensory neurons, and are likely to play a significant role in the analgesic 265 
phenotype of mouse and human Nav1.7-/- mutants 266 
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In conclusion, our data indicate that the loss of Nav1.7 results in a strongly reduced 267 
5-HT pro-nociceptive input, with a concomitant reduction of the intracellular 268 
mediator PKA-RIIβ, as well as a synergistic enhancement of the effectivity of the 269 
opioid receptor on general cAMP mediated anti-nociceptive input. This synergistic 270 
reduction of the counterbalancing system of pain-sensitization signaling is long-271 
lasting and cell autonomous. Further, as this is induced specifically by the loss of 272 
Nav1.7, but not of Nav1.8, this suggests that the cellular homeostatic pro- versus 273 
anti-nociceptive counterbalancing is controlled specifically by Nav1.7. 274 
Discussion 275 
Genetic loss of function of Nav1.7 causes congenital insensitivity to pain in mice 276 
and humans (9, 11, 28), while acute block of Nav1.7 with potent and selective 277 
Nav1.7 antagonists does not (14). This contradiction could be resolved if Nav1.7 278 
contributes not only to electrical activity but also to other cellular processes as well. 279 
Indeed, Minett et al. found in Nav1.7-/- mice that the substance P release in the 280 
spinal cord is abolished (10) and that the opioid activity is tonically increased (15). 281 
These observations may be the consequence of reduced depolarization and thus 282 
reduced secretion while other nociceptor regulatory mechanisms might be left 283 
unchanged. In contrast, our data now prove not only that indeed there are further 284 
cellular pain mechanisms controlled by voltage-gated sodium channels but present 285 
the very first evidence that NaV1.7 especially controls intracellular nociceptive 286 
signaling (see overview scheme in Fig. 7).  287 
Our results highlight the intimate interaction of pro- and anti-nociceptive inputs. 5-288 
HT has been described as a counterplayer of opioids. Accordingly, agonists of 5-289 
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HT4 receptors are used to counteract chronic opioid induced constipation (29, 30) 290 
and in opioid-induced respiratory depression (31). Also at a systemic level, 291 
serotonin-reuptake inhibitors counteract spinal pain-input by increasing the activity 292 
of inhibitory neurons. Our results further support this antagonistic role by showing 293 
5-HT4 receptor signaling and opioid signaling to be tightly functionally interlinked on 294 
a single cell level in a subgroup of peripheral nociceptive neurons.  295 
The pro- and anti-nociceptive input has been shown to scale with stimulus 296 
intensity. Thus, an increased pro-nociceptive input results in a concomitant 297 
increase of the counterbalancing opioid anti-nociceptive intracellular signaling 298 
thereby maintaining a constant net-signaling (27). On the basis of these 299 
observations, our results indicate that Nav1.7 controls this scaling-ratio (Fig. 7). We 300 
find the reduction of the pro-nociceptive serotonergic input in Nav1.7-/- is not 301 
followed by a corresponding reduction of the opioid input. On the contrary, the 302 
effectiveness of opioid signaling was much increased resulting in stronger inhibition 303 
of pRII. Furthermore, Nav1.7 seems not only to control the ratio but also the 304 
maximal endpoint of the opioid effect. While in wildtype animals’ significant pro-305 
nociceptive signaling remains after opioid treatment, this was completely abolished 306 
in Nav1.7-/- neurons (Fig. 5A). This is extremely interesting in the light of the 307 
problem of therapy induced opioid desensitization (8) as well as the low level of 308 
average opioid-induced pain reduction (3-5). Our cellular data now suggest that 309 
Nav1.7 controls synergistically both intracellular changes leading to complete loss 310 
of pain in Nav1.7-/- mice and humans.  311 
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Pre-proenkephalin is upregulated in complete absence of Nav1.7 activity but not 312 
after partial blockade (15). However, GPCRs are known to be modulated quickly by 313 
non-transcriptional changes initiated for example by sodium. Indeed, beyond 314 
transcription sodium regulates a range of cellular processes such as GPCR ligand 315 
binding and allosteric regulation of biased signaling such as the uncoupling of 316 
opioid receptors from its αi signaling while increasing the constitutive signaling 317 
activity through the β-arrestin pathway (32-35). A reduction of intracellular sodium 318 
should therefore result indeed in the observed increased αi signaling activity. But 319 
the specificity of our observations to Nav1.7-/- but not to Nav1.8-/- mice, argues 320 
against large scale sodium changes. Instead, one could speculate about the 321 
importance of differential subcellular localization and of differential Nav1.7/opioid 322 
receptor signaling hubs. But as the knowledge about the role of sodium in signal 323 
transduction still gains momentum, future work needs to detail the mechanism 324 
leading to the described synergistic dampening of pain signaling. 325 
The loss of function of Nav1.7 appears to cause long-term changes to intracellular 326 
nociceptive signaling. We find them to be independent of the continuous presence 327 
of extracellular opioids. These changes result synergistically in reduced pro-328 
nociceptive input but increased long-lasting effectiveness of anti-nociceptive 329 
opioids. This gives proof that sustained dampening of the intracellular pain 330 
signaling in nociceptive neurons can be achieved. Potentially, Nav1.7 therefore 331 
regulates the homeostasis set point of pain signaling. This interpretation would be 332 
in agreement with previous in vivo reports showing the close link of Nav1.7 333 
expression and pain (15, 27, 36, 37). Therefore it is now important to use our novel 334 
cellular endpoints (reduced RIIβ expression, decreased pro-nociceptive input, 335 
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increased relative effectivity of opioid signaling as well as increase of the maximal 336 
effectivity for longtime) together with our novel assay of cellular opioid signaling to 337 
investigate the drugability of this regulator of intracellular pain-signaling. Current 338 
inhibitors of Nav1.7 activity are lacking convincing direct analgesic activity on their 339 
own. Therefore, it will now be of special interest to investigate, in which clinically 340 
relevant pain states the pharmaceutical modulation of Nav1.7 might in combination 341 
with opioid therapeutic translate into prolonging as well as enhancing opioid 342 
effectiveness in mice and humans thereby offering indirectly better pain treatment. 343 
Materials & Methods 344 
Antibodies 345 
The following antibodies were used in this study: chicken polyclonal anti-UCHL1 346 
(1:2000, Novus, Cambridge, UK, #NB110-58872), rabbit monoclonal anti phospho 347 
RIIα (S96) (1:1000, clone 151, Abcam, Cambridge, UK, #ab32390), mouse 348 
monoclonal anti-PKA RIIβ (1:2000, BD Transduction Laboratories, #610625), 349 
highly cross-adsorbed Alexa 647, 594, and 488 conjugated secondary antibodies 350 
(Invitrogen, Carlsbad, CA). 351 
Reagents 352 
5-HT (10 mM in dH2O), naltrexone (100 mM in dH2O), SC-53116 (100 mM in 353 
DMSO), GR113808 (100 mM in DMSO) were purchased from Sigma-Aldrich 354 
(Munich, Germany) and dissolved as indicated. Fentanyl (10 mM in dH2O), 355 
DAMGO (10 mM in PBS), CTOP (5 mM in DMSO), and forskolin (10 mM in DMSO) 356 
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were from Tocris (Bristol, UK). Prostacyclin (10 mM in PBS at pH9.5) was from 357 
Cayman (Ann Arbor, MI). 8-bromoadenosine 3’,5’-cyclic monophosphorothioate, 358 
Sp-isomer and acetoxymethyl ester (Sp-8-Br-cAMPS-AM, 10 mM in DMSO) was 359 
from BIOLOG LSI (Bremen, DE). 360 
Animals 361 
Male Sprague Dawley rats (200-225 g, aged 8-10 weeks) were obtained from 362 
Harlan (Rossdorf, DE) and used for results shown in Fig. 1, 2, and S1. Conditional 363 
Nav1.7 knockout mice were generated by crossing floxed (SCN9A) Nav1.7 mice 364 
with Advillin-Cre mice (10, 28) and global Nav1.8 knockout mice were used (26). 365 
Female and male mice were aged between 6–20 weeks. Mice and rats were kept 366 
on a 12-h light/dark cycle and provided with food and water ad libitum. All animal 367 
experiments were performed in accordance with the German animal welfare law 368 
and approved by the Landesamt für Natur, Umwelt und Verbraucherschutz 369 
Nordrhein-Westfalen or approved by the United Kingdom Home Office according to 370 
guidelines set by personal and project licenses, as well as guidelines of the 371 
Committee for Research and Ethical Issues of IASP. Animals were sacrificed 372 
between 9-12 a.m. by CO2 intoxication. DRGs of rats (L1-L6) or mice (lumbar and 373 
thoracic) were removed within 30 min per animal. 374 
DRG neuron cultures 375 
DRGs were de-sheathed, pooled and incubated in Neurobasal A/B27 medium 376 
(Invitrogen, Carlsbad, CA) containing collagenase P (Roche, Penzberg, DE) (0.2 377 
U/ml, 1 h, 37 C, 5% CO2). The DRGs were dissociated by trituration with fire-378 
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polished Pasteur pipettes. Axon stumps and disrupted cells were removed by BSA 379 
gradient centrifugation (15% BSA, 120 g, 8 min). Viable cells were resuspended in 380 
Neurobasal A/B27 medium, plated in poly-L-ornithine (0.1 mg/ml)/laminin (5 µg/ml)-381 
precoated 96-well imaging plates (Greiner, Kremsmünster, AU) and incubated 382 
overnight (37 °C, 5% CO2). Neuron density was 1500 neurons/cm2. 383 
Stimulation of DRG neurons 384 
DRG neurons were stimulated 24 hours after isolation in 96-well imaging plates. 385 
Compounds were dissolved in 12.5 µl PBS in 96-well V-bottom plates, mixed with 386 
50 µl medium from the culture wells, and added back to the same wells. 387 
Stimulations were performed with automated 8 channel pipettes (Eppendorf, 388 
Hamburg, DE) at low dispense speed on heated blocks, stimulated cells were 389 
placed back in the incubator. The cells were fixed for 10 minutes at room 390 
temperature (RT) by adding 100 µl 8% paraformaldehyde resulting in a final 391 
concentration of 4%. 392 
Immunofluorescence staining 393 
Fixed cells were treated with goat serum blocking (2% goat serum, 1% BSA, 0.1% 394 
Triton X-100, 0.05% Tween 20, 1h, RT) and incubated with respective primary 395 
antibodies diluted in 1% BSA in PBS at 4 °C overnight. Subsequent to three 396 
washes with PBS (30 min, RT) cells were incubated with secondary Alexa dye-397 
coupled antibodies (1:1000, 1h, RT). After three final washes (30 min, RT), wells of 398 
96-well plates were filled with PBS, sealed, and stored at 4 °C until scanning. 399 
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Quantitative microscopy 400 
Stained DRG cultures in 96-well plates were scanned using a Cellomics ArrayScan 401 
XTI with LED light source. Images of 1024 x 1024 pixels were acquired with a 10x 402 
objective and analyzed using the Cellomics software package. Briefly, images of 403 
UCHL1 stainings were background corrected (low pass filtration), converted to 404 
binary image masks (fixed threshold), segmented (geometric method), and 405 
neurons were identified by the object selection parameters size: 80-7500 µm2, 406 
circularity (perimeter2 / 4π area): 1-3, length-to-width ratio: 1-2, average intensity: 407 
800-12000, and total intensity: 2x105-5x107. These image masks were then 408 
overlaid on images obtained at other fluorescence wavelengths to quantify signal 409 
intensities. To calculate spill-over between fluorescence channels, three respective 410 
controls were prepared for each triple staining: (1) UCHL1 alone, (2) UCHL1 + 411 
antibody 1, and (3) UCHL1 + antibody 2. Raw fluorescence data of the controls 412 
were used to calculate the slope of best fit straight lines by linear regression, which 413 
was then used to compensate spill-over as described previously(38). 414 
Compensated data were scaled to a mean value of 1 (or 1000) for the unstimulated 415 
cells to adjust for variability between experimental days. One and two-dimensional 416 
probability density plots were generated using R packages(39). Gating of 417 
subpopulations was performed by setting thresholds at local minima of probability 418 
density plots. The mean number of analyzed neurons was 31,288 ± 3231 (L1-L6 419 
only) per rat and 30965 ± 1438 per mouse (lumbar and thoracic DRGs). 420 
20 
 
Electrophysiology 421 
All electrophysiological recordings were performed using an AxoPatch 200B 422 
amplifier and a Digidata 1440A digitiser (Axon Instruments), controlled by Clampex 423 
software (version 10, Molecular Devices). Filamented borosilicate microelectrodes 424 
(GC150TF-7.5, Harvard Apparatus) were coated with beeswax and fire polished 425 
using a microforge (Narishige) to give resistances of 2-3 M For voltage-clamp 426 
experiments, the following solutions were used. Extracellular solution (values are in 427 
mM): 70 NaCl, 70 Choline.Cl, 3 KCl, 1 MgCl2, 1 CaCl2, 20 tetraethylammonium 428 
(TEA).Cl, 0.1 CdCl2, 0.3 tetrodotoxin (TTX), 10 HEPES, 10 glucose, pH 7.3 with 429 
NaOH. Intracellular solution (values are in mM): 140 CsF, 1 EGTA, 10 NaCl, 10 430 
HEPES, pH 7.3 with CsOH. Unless otherwise stated standard whole-cell currents 431 
were acquired at 25 kHz and filtered at 10 kHz (low-pass Bessel filter). After 432 
achieving whole-cell configuration the cell was left for five minutes to allow for 433 
dialysis of the intracellular solution. A holding potential of -100 mV was applied and 434 
series resistance was compensated by ≥ 70%. All currents were leak subtracted 435 
using a p/4 protocol. To record TTX-resistant sodium currents, a depolarising 436 
voltage-pulse protocol was applied to cell; the cell was held at -100 mV and then 437 
stepped to -15 mV for 50 ms before returning back to -100 mV. This step was 438 
applied every 5 seconds for the duration of the experiment. The cells were 439 
continuously perfused using a gravity-fed perfusion system. All electrophysiological 440 
data were extracted using Clampfit (version 10, Molecular Devices) and analyzed 441 
using GraphPad Prism software (version 6, GraphPad Software).  442 
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Statistical Analysis 443 
Statistical analyses were performed with Students t-tests, one-, or two-way ANOVA 444 
with respective post hoc tests as indicated in the figure legends. P < 0.05 was 445 
considered as statistically significant. HCS dose-response curves were generated 446 
using non-linear regression curve-fitting (three parameter, standard Hill slope) with 447 
Prism (GraphPad, La Jolla, CA). The parameters of the model (top, bottom, or 448 
pEC50/pIC50 values) were compared using the extra-sum-of-squares F test. HCS 449 
kinetic experiments were analyzed with R(39) using ordinary two-way ANOVA. 450 
Bonferroni’s post hoc analysis was applied to determine P values of selected pairs 451 
defined in a contrast matrix using the R library multcomp. Error bars represent the 452 
standard error of the mean (SEM) of 3-5 independent replicate experiments using 453 
cells of different animals.  454 
 455 
Supplementary Materials 456 
Fig. S1. Opioids inhibit PGI2 and forskolin induced pRII increase in rat sensory 457 
neurons. 458 
Fig. S2. Downward-shift of the DAMGO dose-response in the presence of 5-HT. 459 
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Figure Legends 619 
Fig. 1. 5-HT induced increase of pRII is mediated by 5-HT4 receptors and 620 
inhibited by opioids in rat sensory neurons. (A) Experimental outline for 621 
analyzing Gs-and Gi-coupled GPCR signaling in sensory neurons by HCS 622 
microscopy. (B) Representative images of control (Ctrl) and 5-HT stimulated rat 623 
sensory neurons. Green/red encircled neurons indicate automatically 624 
selected/rejected objects. Scale bar, 100 µm. (C) Dose response curve showing 625 
the increase of pRII intensities by 5-HT and the 5-HT4-specific agonist SC-53116. 626 
(D) Induction of pRII by 5-HT was dose-dependently inhibited by the 5-HT4-specific 627 
antagonist GR113808. (E) Fentanyl (Fent) and the MOR-specific agonist DAMGO 628 
(DA) dose-dependently inhibited 5-HT-induced pRII increases. (F) Time-course 629 
experiment indicating long-lasting inhibition of 5-HT (0.2 µM) induced pRII increase 630 
by fentanyl (0.1-10 µM). (G) The opioid receptor antagonist naltrexone (NTX, 10 631 
µM) reversed the fentanyl-induced inhibition of pRII induction. (H) NTX did not 632 
affect baseline or 5-HT induced pRII intensity. (I) The µ opioid receptor antagonist 633 
CTOP (10 µM) partially reverted the inhibition of the 5-HT response by fentanyl. (J) 634 
CTOP did not alter baseline or 5-HT induced pRII intensity. (K) The MOR-specific 635 
agonist DAMGO (0.1-10µM) inhibited the pRII increase induced by 5-HT. (L) The 636 
inhibitory effect of DAMGO was fully reverted by NTX and (M) partially by CTOP. 637 
Values in (C-M) are means ± SEM; n = 3-4 independent experiments; >2000 638 
neurons/condition; two-way ANOVA with Bonferroni’s test; *P<0.05; **P<0.01; 639 
***P<0.001 indicate significance levels between baseline and stimulated 640 
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conditions; §P<0.05; §§P<0.01; §§§P<0.001 indicate significance levels between 641 
stimulated and inhibited conditions. 642 
Fig. 2. Opioids inhibit pRII-increases selectively in RIIβ(+) sensory neurons of 643 
rats. (A) Cell density plots showing single cell data of pRII/RIIβ-labeled rat sensory 644 
neurons stimulated with Fsk (2 µM), 5-HT (0.2 µM), or PGI2 (1 µM) in the absence 645 
(upper panel) or presence (lower panel) of fentanyl (2 µM). Dashed lines indicate 646 
gating thresholds to discriminate between RIIβ(-) and RIIβ(+) neurons with the 647 
numbers indicating the relative percentage of cells in the respective quadrant. 648 
Combined data of n = 4 experiments with a total of >8000 neurons/condition. (B) 649 
Compensation controls showing proper removal of spill-over between fluorescence 650 
channels. (C, D) Mean pRII intensities in RIIβ(-) and RIIβ(+) neurons. Values are 651 
means ± SEM; n = 4 independent experiments; >8000 neurons/condition; two-way 652 
ANOVA with Bonferroni’s test; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 653 
Fig. 3. Loss of Nav1.7 results in downregulation of 5-HT4 receptor and 654 
reduced 5-HT induced pRII increase. (A, B) UCHL1 and pRII intensities in 655 
sensory neurons of Nav1.7 and Nav1.8 knockout mice analyzed by HCS 656 
microscopy. Representative images of control (Ctrl, A) and forskolin (Fsk, B) 657 
stimulated neurons are shown. Green/red encircled neurons indicate 658 
inclusion/rejection of objects for quantification. Scale bar, 100 µm. (C, D) Size and 659 
UCHL1 intensity distributions of sensory neurons did not differ between genotypes. 660 
Probability density estimates (PDE) were derived from >105 neurons analyzed in n 661 
= 4 independent experiments (2 males and 2 females per genotype). (E, F) Real-662 
time PCR quantification of Htr4 mRNA encoding 5-HT4 receptors in Nav1.7-/- and 663 
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Nav1.8-/- mice versus wildtype controls. Data are means ± SEM; n = 6 (3 males and 664 
3 females per genotype), Student’s unpaired t-test. (G) Single cell data of 665 
pRII/RIIβ-labeled sensory neurons after 3 min stimulation with increasing doses of 666 
5-HT. Data represent >3000 neurons/condition from n = 5 females per genotype. 667 
(H) pRII dose-response curve indicating a 37% reduction of the 5-HT response 668 
amplitude in Nav1.7-deficient sensory neurons, but pEC50 values were unchanged. 669 
(I-K) Dose-responses of PGI2 (I), Fsk (J), and Sp-8-Br-cAMPS-AM (K) were similar 670 
in both genotypes. Data in (H-K) are means ± SEM; n = 5 females per genotype; 671 
P<0.0001 for 5-HT top values; extra-sum-of-squares F test. 672 
Fig. 4. Sensory neurons of Nav1.7-/-, but not Nav1.8-/- mice, have a lower basal 673 
pRII level and respond stronger to the opioid receptor agonist fentanyl. (A) 674 
Distribution of RIIβ expression in sensory neurons of Nav1.7-deficient mice (red 675 
line) and wildtype litters (black line). (B) Nav1.7-deficiency resulted in 676 
downregulation of RIIβ in small-to-medium sized sensory neurons, but did not 677 
reduce relative numbers of RIIβ(+) neurons. Data represent>105 neurons/plot; n = 678 
5 females per genotype. (C) Mean RIIβ intensities were 11% lower in RIIβ(+) 679 
neurons of Nav1.7-/- mice compared to wildtype litters. Data are means ± SEM; n = 680 
5 females per genotype, two-way ANOVA with Bonferroni’s test, ****p<0.0001. (D-681 
J) Time-course of pRII intensity after stimulation with fentanyl (Fen, E, 2 µM), 682 
naltrexone (NTX, F, 10 µM), serotonin (5-HT, G, 0.2 µM), combinations thereof (H, 683 
I), or forskolin (Fsk, J, 10 µM). (K-Q) The phenotype observed in Nav1.7-/- mice 684 
was absent in Nav1.8-/- mice. (R) Density plots of pRII intensity vs. cell size 685 
showing single cell data of all neurons shown in (D-J). Data in (D-Q) are means ± 686 
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SEM; n = 4 (2 males and 2 females per genotype); >3000 neurons/condition; two-687 
way ANOVA with Bonferroni’s test; *P<0.05; **P<0.01; ***P<0.001. 688 
Fig. 5. The inhibition of pRII increase by opioids is amplified in Nav1.7-/- mice. 689 
(A) Dose-response of fentanyl in the presence of 5-HT (0.2 µM) indicating a 690 
downward shift in Nav1.7-deficient sensory neurons versus wildtype litters. Data 691 
are means ± SEM; n = 4 females per genotype; P<0.0001 for whole curve; extra-692 
sum-of-squares F test. (B) Combined single cell data of pRII/RIIβ-labeled sensory 693 
neurons shown in (A) representing >2500 neurons/condition. (C) Dose-response 694 
relationship of pRII intensities in sensory neurons of Nav1.7-/- and wildtype (WT) 695 
litters stimulated with increasing doses of fentanyl in the presence of Fsk (2 µM). 696 
Data are means ± SEM; n = 4 females per genotype; P<0.0001 for bottom values; 697 
extra-sum-of-squares F test. (D) Combined single cell data of pRII/RIIβ-labeled 698 
sensory neurons shown in (C) representing >2500 neurons/condition. 699 
Fig. 6. Effect of fentanyl on TTX-resistant Na+ currents from WT and Nav1.7-/- 700 
sensory neurons. (A) Electrophysiological current recording showing TTX-701 
resistant Na+ current before (black) and after (red) the application of fentanyl (100 702 
nM) in wildtype (WT) and Nav1.7-deficient DRG neurons. (B) Change in peak 703 
current (%) of TTX-resistant Na+ current after the application of fentanyl in WT and 704 
Nav1.7-/- DRG neurons. The inhibition of pRII increase by opioids is amplified in 705 
Nav1.7-/- mice. (C) Average change in TTX-resistant Na+ peak current (%) in WT 706 
and Nav1.7-/- DRG neurons after addition of 100 nM fentanyl. Data in (B, C) 707 
represent mean ± SEM; n = 9 neurons per genotype; Student’s unpaired t-test; 708 
***P<0.001. 709 
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Fig. 7. Synergistic regulation of pro- and anti-nociceptive signaling in Nav1.7-710 
deficient mice. Nav1.7-deficiency results in downregulation of 5-HT4 receptors 711 
and their downstream kinase PKA-RIIβ. Thereby, the pro-nociceptive input in 712 
sensory neurons (red) is strongly reduced. Simultaneously, the anti-nociceptive 713 
input (green) is increased due to enhanced opioid receptor activity and 714 
upregulation of endogenous opioid peptides (enkephalins). This synergistic 715 
regulation shifts the balance toward anti-nociceptive mechanisms and thus 716 
contributes to the pain-free phenotype in Nav1.7-deficient mice. 717 
